MULTIPLE MYELOMA

This study tests an experimental drug called linvoseltamab in people with newly diagnosed multiple myeloma. It aims to find the best dose and check if the drug is safe and can shrink tumors. About 149 participants will join, including those who can or cannot have a stem cell tran…

This study tests whether the drug talquetamab can help people with multiple myeloma who have already received a type of immunotherapy called CAR T-cell therapy. The goal is to see if adding talquetamab can keep the cancer from coming back. About 17 adults whose disease is stable …

This study tests a treatment called cilta-cel, a type of CAR-T therapy, for people with multiple myeloma. The goal is to see if it can make the cancer disappear or shrink significantly. About 60 participants will receive the therapy, and researchers will check for signs of cancer…

This study tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will take part. The goal is to see if the combin…

This program offers a special cell therapy called cilta-cel to people with multiple myeloma who have run out of standard options. The treatment is made from the patient's own immune cells and is given when other therapies are not possible. It is only for those who meet strict saf…

This study compares two maintenance treatments for people with high-risk multiple myeloma after initial therapy. One group gets ixazomib plus a lower dose of lenalidomide, the other gets ixazomib alone. The goal is to see which approach better delays the cancer's return. About 10…

This study tests whether adding the experimental drug linvoseltamab after standard initial therapy works better than continuing standard therapy alone for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 1,000 participants will be randoml…

This study tests whether adding isatuximab to the usual drug lenalidomide can better control high-risk multiple myeloma after a stem cell transplant. About 61 adults aged 18 to 72 with newly diagnosed high-risk myeloma will take part. The goal is to see if the combination is safe…

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from an unrelated donor. It compares two ways to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. One method uses a d…

This study tests whether a drug called IgPro20 can reduce infections in people with multiple myeloma who have low antibody levels due to bispecific antibody treatment. About 100 participants will either receive IgPro20 or standard care, and infection rates will be compared over 6…

This early-phase study tests a new cell therapy called LVIVO-TaVec200 in 36 adults with multiple myeloma that has returned or not responded to treatment. The goal is to check safety, find the right dose, and see how long the therapy stays in the body. Participants receive the tre…

This study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …

This study tests a new drug called JNJ-79635322 in people with multiple myeloma that has returned or stopped responding after at least 3 prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer. About 157 participants will receive the drug, and resear…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 250 participants will receiv…

This study tests a 'go-slow' approach for ultra-frail patients newly diagnosed with multiple myeloma. Instead of starting all drugs at once, treatment begins with just two medications, adding a third after two months. The goal is to help these vulnerable patients stick with thera…

This early-phase study tests a new type of CAR T-cell therapy for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have returned or not improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cance…

This early-stage trial tests the safety and best dose of adding venetoclax to three different standard drug combinations for people with a specific genetic subtype of multiple myeloma (t(11;14)). About 100 participants will receive one of the combos. The goal is to see if the new…

This study tests whether adding siltuximab (a drug that blocks a protein called IL-6) to a personalized dose of melphalan (chemotherapy) works better than the standard melphalan dose for people over 60 with multiple myeloma who are getting a stem cell transplant. About 215 partic…

This study tests an experimental drug, etentamig, for adults with multiple myeloma, a blood cancer that often returns or resists treatment. About 440 participants will receive etentamig alone or combined with other cancer drugs to find safe doses and check if it shrinks tumors. T…

This early study tests a new treatment called BCMA-UCART, which uses donor immune cells engineered to find and attack a protein (BCMA) on multiple myeloma cells. It is for adults whose cancer has returned or not responded to at least two prior treatments. The main goals are to ch…

This study tests whether the drug selinexor can safely help people with high-risk multiple myeloma stay in remission longer after CAR-T cell therapy. About 20 participants who have already received CAR-T will take selinexor pills as maintenance. The goal is to see if this approac…

This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) for people with ultra high-risk multiple myeloma that didn't respond well to first treatments. About 20 adults aged 18-65 will receive this one-two punch to see if it's safe and helps control…

This early-phase study tests a new treatment called BMS-986453 for people recently diagnosed with multiple myeloma who are not planning a stem cell transplant. The therapy uses specially engineered immune cells to target two proteins on cancer cells. The main goals are to check s…

This study tests whether two immunotherapy drugs (talquetamab and teclistamab) can eliminate remaining cancer cells in people with newly diagnosed multiple myeloma who still have detectable disease after initial treatment. About 50 participants will receive one or both drugs over…

This early-stage study tests a new drug called TQB2934 for people with multiple myeloma, a type of blood cancer. The drug is designed to help the body's immune cells find and kill cancer cells. About 42 adults aged 18 to 75 will receive the drug as a shot under the skin to check …

This study tests an experimental drug called surzetoclax (ABBV-453) in adults with multiple myeloma that has returned or stopped responding to prior therapies. The drug is given alone or combined with standard anti-myeloma medicines. The goal is to find safe doses and see if the …

This study tests several new drug combinations (teclistamab, talquetamab, and JNJ-79635322) in 160 adults aged 18-70 with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and can improve treatment resp…

This study tests a new drug called cevostamab in 20 Chinese patients whose multiple myeloma has come back or stopped responding to treatment. The goal is to see how the drug moves through the body, if it is safe, and if it helps shrink the cancer. Participants will receive the dr…

This study tests whether the drug elranatamab, given after CAR T-cell therapy (idecabtagene vicleucel), can lower the chance of multiple myeloma worsening. About 32 adults with relapsed or treatment-resistant myeloma will take part. The goal is to see if this combination helps mo…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can shrink or control the cancer as a first-line treatment. About 20 par…

This trial tests whether a combination of two drugs, vemurafenib and cobimetinib, can shrink or control rare cancers that have a specific BRAF V600 mutation. The drugs are already approved for melanoma, and researchers want to see if they help people with other cancer types, like…

This study tests whether adding the drug teclistamab to standard maintenance therapy (lenalidomide) can better prevent multiple myeloma from returning after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment wil…

This study tests a new drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to other treatments. The goal is to find the best dose and check if it is safe and can shrink the cancer. About 387 adults will take part in this early-phase trial.

This study tests whether giving a targeted therapy drug that matches a specific gene change in a person's cancer can shrink tumors or stop them from growing. It includes adults with advanced solid tumors, multiple myeloma, or certain lymphomas who have no standard treatment optio…

This early-phase study tests whether a personalized cancer vaccine (made by fusing a patient's own immune cells with their tumor cells) combined with the drug elranatamab is safe and works for people with multiple myeloma that has come back or stopped responding to prior treatmen…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. About 80 participants will continue treatment and be monitored for side effects. The goal is to keep providing the drug while c…

This study tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective dose. About 140 adults with multiple myeloma will participate. This is an early-stage trial focused on safe…

This early-phase study tests a new injection called JY232 in 9 people with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose. Researchers will also see if the treatment helps shrink the cancer. This …

This study tests a three-drug combination (isatuximab, lenalidomide, dexamethasone) at lower-than-standard doses in 50 adults newly diagnosed with multiple myeloma. The goal is to see if the lower doses can still control the cancer while reducing common side effects. Participants…

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how many patients' tumors shrink or disappear.…

This study tests whether combining Teclistamab or Talquetamab with Daratumumab can delay or prevent multiple myeloma in people with high-risk smoldering myeloma. About 50 participants will receive one of the two drug combinations. The main goal is to see if the treatment can make…

This study looks at whether a specific diet can improve how well people with newly diagnosed multiple myeloma respond to standard chemotherapy and enhance their quality of life. About 220 participants will be assigned to a dietary plan or usual care, and researchers will track tr…

This study tests two new drug combinations (Tal-P and Tal-Tec) against standard treatments for people with multiple myeloma that has come back or stopped responding after 1 to 4 prior therapies. About 795 adults will take part. The goal is to see which combination works better at…

This study looks at whether a special health check-up for older adults (geriatric assessment) can help people aged 60 and older recover faster after CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. The check-up identifies weaknesses in physical function, thinkin…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and infuse th…

This study looks at a three-drug combination (daratumumab, pomalidomide, and dexamethasone) for people with multiple myeloma that has come back after first treatment. About 50 adults will take part to see how well the drugs control the cancer and delay further relapse. The goal i…

This early-stage study tests a new drug called ABBV-438 in about 127 adults with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink the cancer. Participants receive…

This study looks at whether a cancer drug called teclistamab can be given safely in an outpatient clinic instead of the hospital for people with relapsed or refractory multiple myeloma. It involves 15 adults who have already tried at least three other treatments. The goal is to c…

This study is for people whose multiple myeloma has returned or stopped responding to standard treatments, including CAR T-cell therapy. Researchers want to see if combining four drugs—belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone—can shrink the cancer or slo…

This study tests whether giving the drug elranatamab before and after a stem cell transplant can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk myeloma will receive elranatamab to 'purge' cancer cells before transplant and as maintenanc…

This study tests whether a new drug called GR1803 works better than the standard treatment daratumumab (combined with pomalidomide and dexamethasone) for people with multiple myeloma that has returned or stopped responding after 1 to 3 prior treatments. About 358 adults with this…

This early-stage trial tests a new treatment called WS-CART-CS1 for people with multiple myeloma that has come back or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified to target a protein called CS1 found on myeloma cells.…

This study tests a new treatment for people with certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard therapy. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from a dono…

This study tests whether adding the experimental drug elranatamab to two standard medications (daratumumab and lenalidomide) works better than the usual four-drug combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 1…

This study is for Indian adults with multiple myeloma, a blood cancer that has returned or stopped responding to at least three prior treatments. The goal is to check the safety of a drug called teclistamab when given alone. Researchers will track side effects and see how well th…

This program offers the investigational drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of approved treatments and cannot join a clinical trial. It is not a cure but aims to control the disease. Patients must get approval from …

This study is testing a combination of two drugs, mezigdomide and elranatamab, in people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see if the combination is safe and shows early signs of working. Ab…

This early-stage trial tests a new daily pill, KTX-1001, for people with multiple myeloma that has returned or stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors or slow the cancer. About 125 adults who have tried at l…

This study tests whether taking iberdomide after CAR-T cell therapy can keep multiple myeloma under control longer than simply monitoring the disease. About 78 adults who have already received a specific CAR-T treatment will be randomly assigned to either take iberdomide pills or…

This early-phase trial tests a new type of CAR T cell therapy for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses immune cells engineered to recognize and attack myeloma cells, either targeting BCMA alone or both BCMA and CD19.…

This study tests a combination of four drugs (CyBorD plus daratumumab) in 20 people with kidney disease caused by abnormal proteins from a blood condition. The goal is to see if the treatment is safe and can improve kidney function. Participants receive the drugs in cycles, and r…

This study tests a new treatment called GC012F for people with multiple myeloma, a type of blood cancer, that has returned or stopped responding to at least three prior treatments. GC012F uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on cancer…

This study looks at how well umbilical cord blood stem cells from unrelated donors help patients with serious blood cancers, immune problems, or genetic disorders. About 30 people will receive a transplant to see how quickly their blood cells recover and how often the transplant …

This early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and effective for people with multiple myeloma that has returned or not responded to treatment. About 25 adults will receive the vaccine along with CAR-…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or stopped responding to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and atta…

This study is for people newly diagnosed with multiple myeloma, a type of blood cancer. It uses a sensitive test to measure tiny amounts of leftover cancer cells (MRD) after initial treatment. Depending on the results, patients may receive less intensive therapy or a combination …

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests whether adding cyclophosphamide to elranatamab can improve outcomes for people with multiple myeloma that has returned or stopped responding to prior treatments, especially those with risk factors that make standard therapy less effective. About 26 adults with me…

This study tests a personalized approach for people with newly diagnosed multiple myeloma after a stem cell transplant. Instead of a one-size-fits-all maintenance plan, doctors use a sensitive blood test (MRD) to decide if and when to give the drug elranatamab. The goal is to kee…

This study is testing whether adding a drug called Epunamin to a standard chemotherapy regimen (DECP) can help people with multiple myeloma that has come back or stopped responding to treatment. The trial will enroll 48 adults aged 18 to 75 who have already tried at least one pri…

This study tests a drug called belantamab, alone or with other treatments, for people with multiple myeloma (a type of blood cancer). It includes 152 adults whose cancer has come back or not responded to prior therapies. The goal is to find safe doses and see how well the drug co…

This study tests a new drug called etentamig combined with daratumumab for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 660 adults will receive either the new combination or standard treatment. The goal is to see if the new c…

This study tests whether adding linvoseltamab to standard lenalidomide maintenance therapy can eliminate any remaining multiple myeloma cells (MRD negativity) or bring back MRD negativity after a relapse. About 32 adults with newly diagnosed multiple myeloma who have already rece…

This study tests whether two new drug combinations (teclistamab or talquetamab plus daratumumab and lenalidomide) work better than the current standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 1,590 participants will…

This early-phase study tests whether a low-dose radiation and chemotherapy combination before CAR T cell therapy is safe and effective for multiple myeloma patients who also have kidney problems. Standard CAR T prep can be hard on the kidneys, so this approach aims to offer a gen…

This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can help control multiple myeloma that has returned or not responded to treatment, after patients have already received a CAR-T cell therapy called idecabtagene vicleucel. About 49 adults with rel…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 30 people newly diagnosed with multiple myeloma who also have kidney failure. The goal is to see how well the treatment shrinks the cancer and improves kidney function a…

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a patient's own transplant. About 60 adults with multiple myeloma will receive either the drug combo or a placebo. The goal is to see if this approach reduces the number of collectio…

This study tests a new drug, elranatamab, given as a weekly shot, against standard drug combinations for multiple myeloma that has returned or stopped responding to treatment. About 492 adults who have already tried other therapies will take part. The goal is to see if elranatama…

This study offers ongoing treatment with daratumumab for up to 500 adults with multiple myeloma who are already benefiting from it in earlier studies. The goal is to keep providing the drug while monitoring long-term safety, such as serious side effects and infections. Participan…

This early-stage study tests a new treatment called AZD0120 for adults with multiple myeloma, a type of blood cancer. The therapy uses a patient's own immune cells, modified to target two cancer markers (BCMA and CD19). The main goal is to check safety and find the right dose, wh…

This study tests whether adding a vitamin A derivative (ATRA) to standard carfilzomib therapy can make the cancer respond again in people with multiple myeloma whose disease has stopped responding to carfilzomib. About 42 adults who have tried at least three prior treatments will…

This early-phase trial tests a new treatment for multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in the lab with CRISPR gene editing to target and attack cancer cells. About 30 adults will …

This early-phase study tests a drug combination (carfilzomib, cyclophosphamide, dexamethasone, and G-CSF) to safely collect stem cells for transplant in people with multiple myeloma. About 18 participants will receive different doses to find the safest and most effective level. T…

This early-phase study tests a new therapy using a patient's own immune cells (T cells) trained to attack proteins found on myeloma cells. It includes adults with active multiple myeloma or high-risk precursor conditions (MGUS or smoldering myeloma). The main goals are to find a …

This early-phase study tests whether it is safe and possible to collect a patient's own blood stem cells and give them together with CAR-T cell therapy for people with blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain type…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or not improved after prior therapy. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see i…

This study looks at whether a diet with longer overnight fasting and Mediterranean-style eating is practical for people with multiple myeloma or its early forms (MGUS or smoldering myeloma). About 120 adults will try this approach to see if they can stick with it and find it help…

This study tests a new three-drug combination (carfilzomib, iberdomide, and dexamethasone, called KID) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this combo is safe and can improve remission rates before tran…

This study tests whether a new combination of drugs (belantamab mafodotin, lenalidomide, and dexamethasone, or BRd) works better than a standard combination (daratumumab, lenalidomide, and dexamethasone, or DRd) for people newly diagnosed with multiple myeloma who cannot have a s…

This study tests a combination of four drugs (iberdomide, bortezomib, dexamethasone, and isatuximab) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this treatment can achieve a very deep response (stringent complete …

This study tests a new treatment called PD-1Ab21-BCMA CAR-T cells for people with multiple myeloma who also have kidney problems. The therapy uses the patient's own immune cells, modified to better find and attack cancer cells. The goal is to see if this treatment can keep the ca…

This study tests a combination of three drugs—talquetamab, iberdomide, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to other treatments. The goal is to find the safest dose and check for side effects. About 32 adults will take part in …

This study tests a new drug, AZD0305, alone or with other cancer drugs, in about 226 adults with multiple myeloma. The goal is to check safety, find the right dose, and see if it helps control the cancer. Participants must have confirmed multiple myeloma and be in good enough hea…

This study tests whether people newly diagnosed with multiple myeloma or amyloidosis can safely postpone a stem cell transplant if they achieve a very deep response (called minimal residual disease negativity) after 6 cycles of a powerful drug combination. About 40 participants w…

This study tests a new treatment called BCMA-CART, with or without a stem cell transplant, in young adults (18-55) newly diagnosed with multiple myeloma. The goal is to see if it can make the cancer disappear (MRD negative) and keep it away longer. About 50 people will join this …

This study tests a combination of two drugs, belantamab mafodotin and venetoclax, with or without dexamethasone, in people whose multiple myeloma has come back or stopped responding to treatment. The trial focuses on patients with a specific genetic marker called t(11;14). The go…

This study tests whether adding elranatamab to standard drugs (lenalidomide and dexamethasone) can deeply reduce or eliminate cancer cells in people newly diagnosed with multiple myeloma. About 104 participants will receive the combination and be monitored for response. The goal …

This study tests whether two multiple myeloma drugs, teclistamab and talquetamab, can be given safely in an outpatient clinic instead of requiring a hospital stay. About 100 adults with multiple myeloma who have tried at least one prior treatment will receive preventive medicine …

This study tests a new drug, elranatamab, alone or with another drug (daratumumab) in people whose multiple myeloma has returned after at least one prior treatment. About 944 participants will be randomly assigned to one of three groups to see which approach works best and is saf…

This study tests whether giving the drug belantamab mafodotin less often, combined with other standard cancer medicines, can still control multiple myeloma while reducing side effects like eye problems. About 200 adults whose cancer has returned or stopped responding to prior tre…

This study tests an experimental drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has come back after prior therapy. The main goal is to see if the combinations are safe and to find the right dose. About 317 adults with this bl…

This early-phase study tests whether adding the drug mezigdomide after CAR T-cell therapy can help keep multiple myeloma from coming back. It involves 15 adults whose cancer returned after at least four prior treatments. The goal is to find the safest dose and see if it extends t…

This study looks at a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. The goal is to see if using a standard drug alone, with a second drug only when needed, can collect enough stem cells while possibly…

This study is for people with multiple myeloma that has returned or stopped responding to treatment. It tests a drug called belumosudil mesylate, given alone or with a steroid (dexamethasone), to find the best dose and see if it can control the cancer. About 36 participants will …

This study is for people aged 65 or older who have been newly diagnosed with multiple myeloma and cannot have a stem cell transplant. Researchers are testing two different drug combinations: teclistamab plus daratumumab, or teclistamab plus lenalidomide. The goal is to see if the…

This study looks at 450 adults with multiple myeloma who have a type of kidney damage called light chain cast nephropathy. Researchers want to see if plasma exchange or a drug called daratumumab helps the kidneys recover better than other treatments. The goal is to improve surviv…

This study tests a treatment plan that adjusts based on each patient's frailty level for elderly people newly diagnosed with multiple myeloma. The goal is to see if tailoring therapy can improve response rates and reduce treatment side effects. About 131 participants aged 65 and …

This study tests if the antiviral drug remdesivir can safely treat RSV (a common respiratory virus) in 60 adults whose immune systems are weakened by certain cancer or autoimmune treatments. Participants must have a confirmed RSV infection with symptoms. The main goal is to see i…

This study looks at whether people with relapsed multiple myeloma can safely inject the drug elranatamab at home instead of going to a clinic. About 20 participants will track side effects, time spent, and quality of life. The goal is to see if home treatment is safe, practical, …

This study tests whether switching between two different drug combinations can safely and effectively treat people newly diagnosed with multiple myeloma. About 65 participants will receive one combination for 3 cycles, then switch to another for 3 more cycles. The goal is to see …

This study is testing several treatment combinations for people with multiple myeloma, a type of blood cancer. The goal is to see which treatments are safest and work best. About 200 participants will be enrolled, and the study can add new treatments as they become available.

This study tests a proactive care program called PASCA for adults aged 18 to 70 with multiple myeloma who have had a stem cell transplant. The program involves regular check-ups and early referrals to specialists to manage complications like high blood pressure, kidney problems, …

This study tests an experimental drug, enzomenib, in people with acute leukemia and other blood cancers that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 600 participants will take part in t…

This early-stage study tests whether combining teclistamab and mezigdomide is safe and works for people with multiple myeloma that has returned or not responded to prior treatments. About 18 adults who have already tried at least two other therapies will take part. The main goal …

This study tests a new drug called cemsidomide combined with dexamethasone in about 100 adults whose multiple myeloma has returned or stopped responding after at least three prior treatments. The goal is to see how well the combination shrinks tumors and how safe it is. Participa…

This study tests a new drug, JNJ-79635322, against another targeted therapy for people with multiple myeloma that has returned or stopped responding after at least three prior treatments. About 400 participants will be randomly assigned to one of the two treatments. The goal is t…

This study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive diffe…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares two treatment plans: taking the drugs daratumumab or isatuximab continuously versus stopping them after about 18 months. The goal is to see if a shorter treatm…

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This study looks at how HyQvia, a treatment to boost the immune system, is used in real-world clinics for people with multiple myeloma who have a weakened immune system (secondary immunodeficiency). Researchers will track details like dose, infusion speed, and where the treatment…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This early-stage study tests two drugs—elranatamab (a shot under the skin) and iberdomide (a pill)—in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see how well the combination works. About 87 adults with myelom…

This study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. About 20 adults with certain blood cancers (like lymphoma, myeloma, or leukemia) will receive …

This study tests whether giving immune globulin (IGI) infusions regularly can prevent serious infections in adults with multiple myeloma who are receiving a type of immunotherapy called bispecific antibody therapy. About 183 participants will be randomly assigned to receive IGI e…

This study tests a new treatment called anitocabtagene autoleucel (a type of cell therapy) against the usual treatments for multiple myeloma that has returned or not responded after 1 to 3 prior therapies. About 450 adults will take part. The goal is to see if the new therapy can…

This study tests a combination of four drugs (bortezomib, isatuximab, cyclophosphamide, and dexamethasone) in people with newly diagnosed multiple myeloma who also have kidney problems and are eligible for a stem cell transplant. The goal is to see how well this treatment shrinks…

This study tests whether targeted radiation can help control multiple myeloma that remains active after CAR-T cell therapy. About 30 adults who still have signs of disease on scans after CAR-T will receive radiation to up to five tumor spots. The goal is to see if this approach i…

This study tests a drug called elranatamab in people with multiple myeloma that has returned or not responded to previous treatments. About 33 participants who have already tried 1 to 3 other therapies will receive elranatamab alone. The goal is to see if the drug can make cancer…

This early-stage study is testing a cell therapy called arlocabtagene autoleucel combined with other drugs (alnuctamab, mezigdomide, iberdomide, or elranatamab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has returned or stopped responding to at least four prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to…

This study is testing a new drug, CC-92480, combined with other therapies for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink tumors. About 260 participants will take part in this…

This study tests whether a new drug, iberdomide, works better than the current standard lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays canc…

This expanded access program provides a CAR T-cell therapy called ide-cel to people with multiple myeloma whose specially made treatment batch did not meet commercial standards. The goal is to offer a treatment option when no other suitable therapy is available. Participants must…

This study tests whether adding targeted radiation to the drug talquetamab can safely and effectively treat multiple myeloma that has spread to organs or soft tissues (extramedullary disease). About 20 adults with this difficult-to-treat condition will receive radiation to one tu…

This early-phase study tests a new type of cell therapy (CAR19-BCMA CAR-T) for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The main goal is to ch…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests whether a prebiotic (resistant starch) can improve gut microbiome diversity in 30 people with multiple myeloma or lymphoma undergoing autologous stem cell transplant. Participants take the prebiotic or a placebo for about 10 days before and until engraftment. The…

This study is testing whether a two-drug maintenance therapy can help control multiple myeloma in patients who still have small amounts of cancer cells after a stem cell transplant. The treatment involves regular infusions of one drug and daily pills of another, taken long-term t…

This early-stage study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans in 20 people with multiple myeloma. The tracer targets a protein (CD46) found on some myeloma cells, which may help doctors see cancer more clearly than standard scans. The main goals are to …

This study is testing a new platform that uses advanced genetic and functional tests to better understand tumors from 300 people with various high-risk cancers, including leukemia, myeloma, and pancreatic cancer. The goal is to see if this detailed analysis can change the recomme…

This early-phase study tests a new PET imaging probe called 68Ga-NB381 that targets a protein (CD38) found on multiple myeloma cancer cells. The goal is to see if this scan can detect the disease more accurately than current methods, potentially reducing the need for invasive bon…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early and tell which type it is. In people with lung cancer, the test will also check for any cancer…

This study aims to find multiple myeloma at its earliest, precancerous stage (MGUS) in people at higher risk—Black adults and those with a family history of plasma cell disorders. By screening with a simple blood test, researchers hope to catch the disease before it causes seriou…

This study looks at why people with multiple myeloma fall and tests a home exercise program to prevent falls. About 60 adults on cancer therapy will use a training app for 24 weeks. The goal is to find fall risks and see if the exercises are practical and reduce fear of falling.

This study tests a telemedicine program called FOCUS for people with advanced cancer. The program uses counseling techniques to help manage common symptoms like trouble sleeping, worry, tiredness, and low mood. Researchers will enroll 120 adults with advanced lung, breast, prosta…

This study tests a personalized exercise program for 120 multiple myeloma patients who are about to have a stem cell transplant. The goal is to see if the program reduces fatigue and improves quality of life. Patients will follow an adapted physical activity plan designed to be e…

This study looks at whether a 10-week exercise program, done in-person or online, can help people with multiple myeloma maintain their physical fitness, muscle strength, and quality of life while they undergo chemotherapy before a stem cell transplant. The trial will include 30 a…

This study tests whether a combination of three anti-nausea drugs (fosaprepitant, tropisetron, and olanzapine) works better than the standard combo to prevent delayed nausea and vomiting after high-dose chemotherapy in multiple myeloma patients receiving their own stem cells. Abo…

This study tests whether a medication called budesonide can prevent severe diarrhea in people with multiple myeloma who are getting a stem cell transplant. About 120 adults will be randomly assigned to receive either budesonide or a placebo alongside standard care. The goal is to…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…

This study tests whether giving cancer treatment at home is preferred over going to a clinic. It involves 27 adults with various cancers in the Florida Panhandle. The goal is to see if home care improves patient satisfaction and is safe.

This study tests whether an 8-week home exercise program, done before a stem cell transplant, can improve muscle strength and physical fitness in people with multiple myeloma. About 30 adults will either exercise with virtual coaching or continue normal activities. The goal is to…

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will either get early palliative care plus standard care or standard care alone. Resea…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of life by min…

This study tests whether a prehabilitation program (exercises and support before transplant) can help adults aged 60 and older with multiple myeloma maintain physical function during stem cell transplant. Thirty participants will be randomly assigned to either the prehabilitation…

This study looks at whether adding palliative care (extra support for symptoms and stress) to usual cancer care can improve quality of life for adults with lymphoma, leukemia, or multiple myeloma who are receiving cell therapy. About 90 participants will be randomly assigned to e…

This study is for people with multiple myeloma whose doctors recommend radiation. Normally, radiation takes 2-3 weeks, but this trial tests a shorter course (hypofractionation) with slightly higher daily doses to see if it is safe. About 30 participants will receive pelvic radiat…

This study tests whether a home-based program combining gentle physical activity, mindfulness, and telephone health coaching can reduce fatigue and improve quality of life in people aged 65 and older with multiple myeloma. Participants will use a remote monitoring device and rece…

This study tests whether adding a non-opioid painkiller (ketorolac) to standard opioid pain medicine can reduce the amount of opioids needed after preventive thigh bone surgery. The surgery is for patients with cancer that has spread to the thigh bone but who do not have a broken…

This study compares two premedication regimens—methylprednisolone versus dexamethasone—to prevent allergic reactions to motixafortide in multiple myeloma patients undergoing stem cell collection. About 94 adults will participate to see which steroid works better and has fewer sid…

This study is a long-term observation of 1,000 patients receiving stem cell transplants for blood diseases at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on patient health, treatment results, and costs to understand how high altitude affects reco…

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like lymphoma, leukemia, or multiple myeloma. The tool helps patients clarify what matters most to them and shares that with their doctors. The goal is to see if using PRIME lead…

This study follows 30,000 people who have early blood changes (MGUS or smoldering myeloma) that can lead to multiple myeloma. Researchers want to learn what makes some people's condition get worse over time. Participants are African American or have a close family member with a r…

This study collects blood, urine, and tissue samples from up to 10,000 people with or suspected of having amyloid diseases, such as multiple myeloma. The goal is to build a large repository of samples and data to help researchers better understand these conditions in the future. …

This study looks at how common sleep apnea is in people with MGUS or multiple myeloma, and whether it affects the bone marrow. Researchers will collect bone marrow samples during standard biopsies from 200 participants. The goal is to understand how sleep apnea might influence th…

This study collects tissue and fluid samples (like blood, urine, and tumor tissue) from up to 5,000 children and adults with cancer at the NIH Clinical Center. The samples are used for research only, not for direct treatment. The goal is to help scientists learn more about cancer…

This study is creating a large database of people with various blood diseases in China, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, out…

This study aims to understand how a specific sugar modification (N-glycosylation) on abnormal proteins contributes to AL amyloidosis, a rare disease where these proteins build up and damage organs. Researchers will analyze blood and bone marrow samples from 100 adults with relate…

This study looks at how the blood thinner apixaban affects blood clotting in two groups: people newly diagnosed with multiple myeloma and people recovering from total knee replacement surgery. Both groups are at high risk for dangerous blood clots. Researchers want to see if the …

This study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma. Researchers will collect DNA and blood samples from people who have these cancers and their family members. No treatment is given—the goal is to learn more about why…

This study looks at whether a tailored exercise program can slow down the aging process in people aged 50 and older who have survived blood cancers like leukemia or lymphoma. Researchers want to find out how much and what type of exercise is needed to make a difference. The goal …

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood cancers and related disorders on PET/CT scans. About 30 adults with non-Hodgkin lymphoma, multiple myeloma, or histiocytic neoplasms will receive the agent an…

This study looks at whether a simple early warning score (based on vital signs like breathing and heart rate) can help doctors spot serious problems early in blood cancer patients receiving strong chemotherapy. About 2,200 adults will take part across 10 hospitals. Half the hospi…

This study looks at whether firefighters' exposure to dangerous chemicals on the job raises their risk of developing blood cancers. Researchers will test blood samples from 300 firefighters in Charlotte, NC, for early signs of cancer, such as abnormal blood cells or proteins. The…

This study tests whether an AI tool can create a personalized list of questions for people with lymphoma or multiple myeloma to use during their doctor appointments. About 40 participants will use the AI-generated list and then report how confident they felt communicating and how…

This study is testing whether daily voice recordings made on a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will record their voi…

This study looks at whether people with multiple myeloma who have achieved a very deep remission (called MRD-negative) and have been on maintenance therapy for at least two years can stop that therapy without their cancer coming back. Researchers will follow 70 participants for u…

This study is building a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will collect information on frailty, muscle loss, and other age-related health issues. No treatments are given—the goal is to gather data to supp…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn why some cancers respond differently to treatment. The goal is to develop more effective therapies in the future.

This study tests whether people with multiple myeloma who have no detectable cancer cells (called minimal residual disease negative) can safely stop their daily maintenance drugs after a stem cell transplant. Researchers will watch 50 participants for one year to see if the cance…

This study is for people with advanced cancer (solid tumors, lymphoma, or multiple myeloma) that has stopped responding to standard treatments. Researchers will test the tumor's genes to find a targeted drug that might work. The goal is to learn from real-world use which drugs he…

This study follows 700 people with multiple myeloma to see how cannabis use affects their quality of life and symptoms during chemotherapy. Researchers will compare cannabis users and non-users using surveys and medical reports. The goal is to understand potential benefits and ha…

This study is gathering basic health and survival information from 2000 people who are getting a stem cell transplant for blood cancers or immune diseases. The goal is to build a database that doctors can use to improve care and answer future questions. No experimental treatments…

This study looks at how a specific gene (IGLV1-44) causes two rare blood disorders: AL amyloidosis and POEMS syndrome. Researchers will analyze blood and bone marrow samples from 100 adults with these conditions or multiple myeloma. The goal is to find unique patterns in the gene…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study watches how older patients (age 60 and up) with certain blood cancers handle standard CAR-T cell therapy and how it changes their daily life and thinking skills. No extra treatment is given—just careful checkups. The goal is to see if patients can complete all planned …

This study looks at tumor samples from 50 people who developed a second cancer after receiving a BMS-made CAR-T cell therapy. Researchers will test whether the original treatment's genes are present in the new tumor. The goal is to understand if the therapy played a role, not to …

This study aims to understand why multiple myeloma affects African American, Latino, Asian American, and non-Hispanic White people differently. Researchers will survey 4000 patients in California about their experiences and health outcomes. The goal is to find better ways to stud…

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. Researchers will use ultrasound to check heart function in 60 patients before and a few days after treatment. The goal is to find out how often these heart is…

This study looks at how a short-term plant-based diet or supplements (omega-3, curcumin, or probiotics) change levels of butyrate—a healthy gut substance—in people with smoldering multiple myeloma or MGUS. About 200 participants will be assigned to one of the diet or supplement g…

This study is for people with advanced cancers who are taking targeted treatments for months or years. Researchers will interview 75 participants to understand their experiences and needs. The goal is to find better ways to support patients living with chronic cancer treatments.

This study is following 2,000 people with multiple myeloma in the West-Occitanie region of France to see how they are actually treated in everyday medical practice, not just in controlled clinical trials. Researchers will track which drugs and procedures patients receive, how wel…

This study looks at the genetic makeup of multiple myeloma tumors in 100 people with relapsed disease. Researchers will analyze blood, cheek swab, and tumor samples to find gene changes and understand how the cancer works. The goal is to gather information that could guide future…

This study aims to gather information from cancer patients (breast, lung, ovarian, multiple myeloma, or AML) who use a remote symptom monitoring system during their routine treatment. Participants will complete weekly surveys about their symptoms for at least 12 weeks. The goal i…

This study is building a registry of 2,000 adults with plasma cell disorders, such as multiple myeloma and amyloidosis. Participants will fill out health questionnaires and may give a blood sample to study aging markers. The goal is to gather information to support future researc…

This study is a large registry that will follow about 2,200 people with multiple myeloma in Germany. Its goal is to collect information on what treatments patients actually receive, how well they work, and how patients feel over time. Participants will have their medical data and…

This study aims to understand why some people develop long-lasting low blood cell counts (cytopenia) after CAR-T therapy for multiple myeloma or certain lymphomas. Researchers will analyze participants' genes to find changes that might increase this risk. The goal is to better pr…

This study looks at how certain immune cells (monocytes) influence the response to CART cell therapy in people with multiple myeloma. Researchers will analyze blood samples before and after treatment to find factors that predict better outcomes. The goal is to improve understandi…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…

This study is testing a drug called Imuthiol (Zn-DDC) in the laboratory to see if it can kill cancer stem cells from patients with multiple myeloma or acute leukemia. Researchers want to find out if Imuthiol, alone or combined with other drugs, could lead to an effective and affo…

This study is testing whether a monthly monitoring program called ICOPE can help detect early signs of decline in people over 70 with multiple myeloma. The goal is to prevent loss of independence by catching problems early. About 30 participants will use a smartphone app or chatb…

This study is creating a large database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information ab…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study tests whether a new radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the current standard tracer on PET/CT scans. About 60 adults with newly diagnosed or relapsed/refractory multiple myeloma will receive both tracers and have their sca…

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for delayed side effects, such as new cancers, nerve problems, or serious infections. No new treatment is given—participants are simply monitored o…

This study collects blood and tissue samples from 6,000 people with multiple myeloma, smoldering myeloma, plasma cell leukemia, or MGUS. Researchers will store these samples in a biobank to study the diseases and improve future care. Participants do not receive any treatment as p…

This study looks at why some families have more blood cancers like lymphoma, leukemia, and myeloma. Researchers will study the genes and environment of 3000 people who have at least two living relatives with these cancers. The goal is to find inherited factors that raise risk, no…

This study is following 1,000 adults with early signs that can lead to multiple myeloma (a blood cancer). The goal is to learn why some people's condition gets worse while others stay stable. Researchers will use advanced genetic tests to look for key changes in the bone marrow. …

This study watches how well a combination of three drugs (selinexor, bortezomib, and dexamethasone) works for adults with multiple myeloma who have already tried 1 to 3 other treatments. It does not test a new drug but collects information from regular medical care to see how lon…

This study collects blood, urine, bone marrow, and tissue samples from adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand these diseases, which may lead to new ways to diagnose or treat them. No treatment is given as part of…